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Abstract
There is long-standing recognition that transformed and tumor cells
exhibit striking alterations in nuclear morphology as well as in the rep-
resentation and intranuclear distribution of nucleic acids and regulatory
factors. Parameters of nuclear structure support cell growth and pheno-
typic properties of cells by facilitating the organization of genes, replica-
tion and transcription sites, chromatin remodeling complexes, transcripts,
and regulatory factors in structurally and functionally definable sub-
nuclear domains within the three-dimensional context of nuclear archi-
tecture. The emerging evidence for functional interrelationships of
nuclear structure and gene expression is consistent with linkage of tumor-
related modifications in nuclear organization to compromised gene regu-
lation during the onset and progression of cancer.
Introduction
The rules that govern nuclear architecture remain to be established.
However, there is long-standing recognition that transformed and
tumor cells exhibit striking alterations in nuclear morphology as well
as in the representation and intranuclear distribution of nucleic acids
and regulatory factors. The emerging evidence for functional interre-
lationships of nuclear structure and gene expression is consistent with
linkage of tumor-related modifications in nuclear organization to
compromised gene regulation during the onset and progression of
cancer.
The contributions by multiple levels of nuclear organization to
control of gene expression will be evaluated. We will focus on the
conceptual and experimental basis for the hypothesis that parameters
of nuclear structure support cell growth and phenotypic properties of
normal and tumor cells by facilitating the organization of genes,
chromatin remodeling complexes, transcripts, and regulatory factors
within the three-dimensional context of nuclear architecture. We will
address perturbations in mechanisms that direct regulatory factors to
subnuclear sites that may contribute to aberrations in control of
transcription and posttranscriptional processing of gene transcripts.
Components of Nuclear Organization Contributing to Control
of Gene Expression
As the complexities of transcriptional control become increasingly
evident, there is growing awareness that the fidelity of gene regulation
necessitates coordination of transcription factor metabolism and the
spatial organization of genes and regulatory factors. There is compel-
ling evidence that multiple components of nuclear architecture con-
tribute to the activation and suppression of genes. Mechanisms that
are operative in vivo include transcription factor synthesis, nuclear
import and retention, posttranslational modifications of factors, and
the direction of factors to subnuclear sites that support gene expres-
sion. Factor turnover is subject to a series of regulatory steps. Plas-
ticity is essential to accommodate the stringent requirements for gene
expression in a biologically responsive manner. Remodeling of chro-
matin and nucleosome organization to accommodate protein-DNA
and protein-protein interactions at promoter elements is key to phys-
iological control of transcription. The reconfiguration of gene pro-
moters and assembly of specialized subnuclear domains reflect the
orchestration of both regulated and regulatory mechanisms.
From a biological perspective, each biochemical parameter of fac-
tor metabolism and activity requires control, and components of
nuclear organization are linked to structure-function interrelationships
that mediate the transcription and processing of gene transcripts.
However, rather than representing regulatory obstacles, the complex-
ities of nuclear biochemistry and morphology provide the required
specificity for physiological responsiveness to a broad spectrum of
signaling pathways to modulate transcription under diverse circum-
stances. It is therefore understandable why modifications in nuclear
architecture and nuclear structure-function interrelationships accom-
pany and appear to be causally related to compromised gene expres-
sion and DNA replication under pathological conditions.
Sequence Organization. Appreciation is accruing for the high
density of information in both regulatory and mRNA coding se-
quences of cell growth and phenotypic genes. The modular organiza-
tions of promoter elements provide blueprints for responsiveness to a
broad spectrum of regulatory cues that support competency for tran-
sient developmental and homeostatic control as well as sustained
commitments to tissue-specific gene expression. Overlapping recog-
nition elements expand the options for responsiveness to signaling
cascades that mediate mutually exclusive protein-DNA and protein-
protein interactions. Splice variants for gene transcripts further en-
hance the specificity of gene expression. However, the linear order of
genes and flanking regulatory elements is necessary but insufficient to
support expression in a biological context. There is a requirement to
integrate the regulatory information at independent promoter elements
and selectively utilize subsets of promoter-regulatory information to
control the extent to which genes are activated and/or suppressed.
Chromatin Organization. Chromatin structure and nucleosome
organization provide architectural linkages between gene organization
and components of transcriptional control. During the past two de-
cades, biochemical and structural analyses have defined the dimen-
sions and conformational properties of the nucleosome, the primary
unit of chromatin structure. Each nucleosome consists of approxi-
mately 200 bp of DNA wrapped in two turns around an octameric
protein core containing two copies each of histones H2A, H2B, H3,
and H4. A fifth histone, the linker histone H1, binds to the nucleosome
and promotes the organization of nucleosomes into a higher-order
structure, the 30-nm fiber. Nucleosomal organization reduces dis-
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tances between promoter elements, thereby supporting interactions
between the modular components of transcriptional control. Higher-
order chromatin structure further reduces nucleotide distances be-
tween regulatory sequences. Folding of nucleosome arrays into sole-
noid-type structures provides a potential for interactions that support
synergism between promoter elements and responsiveness to multiple
physiological regulatory signals.
It has been well established that the presence of nucleosomes
generally blocks the accessibility of transcription factors to their
cognate binding sequences (1). Extensive analyses of chromatin struc-
ture have indicated that the most active genes exhibit increased
nuclease hypersensitivity at promoter and enhancer elements. These
domains generally reflect alterations in the classical nucleosomal
organization and the binding of specific nuclear factors. Thus, DNase
I digestion has been widely used to probe structures in vivo and in
vitro based on the premise that chromatin accessibility to DNase I
reflects chromatin access to regulatory molecules in the nucleus.
Changes in chromatin organization have been documented under
many biological conditions in which modifications in gene expression
are necessary for the execution of physiological control. Developmen-
tal and steroid hormone-related changes in the chromatin organization
of the globin and ovalbumin genes served as the initial examples of
chromatin remodeling linked to gene expression (2–4). Although
these studies predated the identification and characterization of pro-
moter elements and cognate-regulatory factors, they provided the
foundation for examining the control of nucleosome placement as a
component of transcriptional control.
Transient changes in chromatin structure of a human cell cycle-
regulated histone H4 gene illustrate remodeling of chromatin organi-
zation to support competency for gene expression during cell cycle
progression at the G1-S-phase transition (5, 6). By combining DNase
I digestion of isolated nuclei, indirect end labeling, and genomic
sequencing, it was found that two regions in the proximal promoter of
this gene exhibit cell cycle-dependent changes in chromatin structure.
These regions contain key elements for both basal transcription and
cell cycle regulation (7, 8).
Alterations in the chromatin organization of the bone tissue-specific
and steroid hormone-responsive osteocalcin gene promoter during
osteoblast differentiation provide a paradigm for remodeling chroma-
tin structure and nucleosome organization that is linked to long-term
commitment to phenotype-specific gene expression (9, 10). Transcrip-
tion of the osteocalcin gene in late-stage, postproliferative osteoblasts
(11, 12) is controlled by a modularly organized promoter with prox-
imal basal regulatory sequences and distal hormone-responsive en-
hancer elements (13–22). Modifications in chromatin structure and
nucleosome organization at these two promoter regulatory domains
parallel competency for transcription and the extent to which the
osteocalcin gene is transcribed in response to physiological mediators
of basal expression and steroid hormones. This remodeling of chro-
matin provides a basis for the involvement of nuclear architecture in
growth factor- and steroid hormone-mediated control of osteocalcin
gene expression during osteoblast differentiation. Basal expression
and enhancement of osteocalcin gene transcription are accompanied
by two changes in the structural properties of chromatin. DNase I
hypersensitivity of sequences flanking the basal, tissue-specific ele-
ment and the vitamin D enhancer domain are observed (9, 23, 24).
Together with changes in nucleosome placement (23), a basis for
accessibility of transactivation factors to basal and steroid hormone-
dependent regulatory sequences can be explained. In early-stage pro-
liferating osteoblasts, when the osteocalcin gene is repressed, nucleo-
somes are placed in the proximal basal domain and in the vitamin
D-responsive enhancer promoter sequences. Nuclease-hypersensitive
sites are not present in the vicinity of these regulatory elements. In
contrast, when osteocalcin gene expression is transcribed postprolif-
eratively and vitamin D-mediated enhancement of transcription oc-
curs, the proximal basal and upstream steroid hormone-responsive
enhancer sequences become nucleosome free, and these regulatory
domains are flanked by DNase I-hypersensitive sites.
Among the studies that have established a role for nucleosomes
regulating steroid hormone transcriptional activation, Archer et al.
(25) have shown that in cell lines stably transfected with the MMTV3
constructs, positioned nucleosomes found at the long terminal repeat
sequence prevent binding factors such as NF-1 to its cognate site.
After ligand activation, glucocorticoid receptor can bind to a site
located proximal to the NF-1 binding sequence. A hormone-depen-
dent DNase I-hypersensitive site is generated that renders the NF-1
element available for occupancy and competent for interactions with
components of the transcriptional initiation complex (26).
Although it has been known for some time that regulatory activity
of the vitamin D receptor requires chromatin remodeling to facilitate
the accessibility of promoter-regulatory sequences, direct linkage of
histone modifications with altered activities of steroid hormone-
responsive promoter elements has been elusive. However, recent
reports indicate that coactivators and repressors that interact with the
vitamin D receptor include HATs and HDs (27). Modifications have
been demonstrated in the acetylation of histones in nucleosomes
associated with vitamin D receptor promoter sequences (27). These
findings provide valuable insight into mechanisms linking changes in
the placement and organization of nucleosomes with the control of
transcription. Acetylation neutralizes positive charges of lysine resi-
dues and disrupts the association of HAT coactivator complexes with
promoter-associated steroid hormone receptors. In vivo evidence is
thereby provided for a key role of histone acetylation in steroid
hormone-induced gene activation, and cofactor acetylation is impli-
cated in hormonal signaling (27).
The Nuclear Matrix. As the intricacies of gene organization and
regulation are elucidated, the requirement to resolve a fundamental
biological paradox becomes increasingly evident. With a limited
representation of gene-specific regulatory elements and a low abun-
dance of cognate transcription factors, how can a threshold concen-
tration for sequence-specific interactions be attained to support the
initiation of transcription within nuclei of intact cells? Resolution is in
part provided by contributions of the nuclear matrix to transcriptional
control. It was this paradox, together with ultrastructural, biochemical,
and molecular genetic evidence for involvement of nuclear architec-
ture, that prompted the consideration of contributions by the nuclear
matrix to control of gene replication and expression (28–31).
The anastomosing network of fibers and filaments that constitutes
the nuclear matrix supports the structural properties of the nucleus as
a cellular organelle and accommodates modifications in gene expres-
sion associated with proliferation and differentiation and changes
necessary to sustain phenotypic requirements in specialized cells (30,
32–34). Regulatory functions of the nuclear matrix include but are by
no means restricted to DNA replication (28), gene localization (35),
imposition of physical constraints on chromatin structure that support
the formation of loop domains, concentration and targeting of tran-
scription factors (36–41), RNA processing and export of gene tran-
3 The abbreviations used are: MMTV, mouse mammary tumor virus; NF, nuclear
factor; HAT, histone acetyltransferase; HD, histone deacetylase; SAGA, Spt-Ada-Gcn5-
acetyl transferase; NuRD, nucleosome remodeling HD; CBP, CREB-binding protein;
CREB, cAMP-responsive element-binding protein; AML, acute myelogenous leukemia;
ALL, acute lymphocytic leukemia; PML, promyelocytic leukemia; MLL, mixed lineage
leukemia; ACTR, activator of retinoic acid receptor; TRAM, thyroid receptor activator
molecule; SRC, steroid receptor coactivator; RAC, receptor-associated coactivator;
P/CAF, p300/CBP-associated factor; SMRT, silencing mediator of retinoic acid and
thyroid hormone receptor; CBFa, core binding factor a; PEBPa, polyoma enhancer
binding protein a; RUNX, runt-related.
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scripts (42–46), posttranslational modifications of chromosomal pro-
teins, and modifications of chromatin structure (47). Additional
linkages between nuclear architecture and gene expression have re-
cently been provided by biochemical and in situ immunofluorescence
evidence showing that components of the RNA transcription complex
are nuclear matrix associated and that nuclear matrix-associated sites
of replication exhibit modified subnuclear distribution during the cell
cycle (48).
Subnuclear Domains. An understanding of interrelationships be-
tween nuclear structure and gene expression necessitates knowledge
of the composition, organization, and regulation of sites within the
nucleus that are dedicated to replication, transcription, and processing
of gene transcripts. During the past several years, there have been
developments in reagents and instrumentation to enhance the resolu-
tion of nucleic acid and protein detection by in situ hybridization and
immunofluorescence analyses. The combined application of isotopic
and nonisotopic methods, together with a new generation of high-
resolution techniques for quantitation and three-dimensional recon-
struction from digitally captured images, is providing new insights
into the intranuclear distribution of genes and regulatory factors (Fig.
1). We are beginning to make the transition from descriptive in situ
mapping of genes, transcripts, and regulatory factors to visualization
of gene expression from the three-dimensional perspective of nuclear
architecture. Initially, in situ approaches were primarily used for
intracellular localization of nucleic acids and proteins that were first
shown by biochemical analyses to contribute to the control of gene
expression. We are now applying high-resolution in situ analyses for
the primary characterization of gene-regulatory mechanisms under in
vivo conditions.
We are increasing our understanding of the significance of nuclear
domains to the control of gene expression. These local nuclear envi-
ronments generated by the multiple aspects of nuclear structure sup-
port developmental expression of cell growth and tissue-specific
genes. Initially, control of gene expression and characterization of
structural features of the nucleus were conceptionally and experimen-
tally pursued as minimally integrated questions. However, independ-
ent pursuit of nuclear structure and function has occurred in parallel
with the appreciation that several components of nuclear architecture
are associated with parameters of gene expression or control of
specific classes of genes. There is long-standing acceptance that the
nucleolus is a site of ribosomal gene expression. The nuclear pore is
recognized as a site for facilitating the import and retention of gene-
regulatory factors as well as the export of transcripts (Ref. 49; re-
viewed in Ref. 50). SC35 domains have been studied extensively from
the standpoints of RNA splicing and the dynamic recruitment of
transcript processing factors (44, 51–54). Subnuclear sites where
transcription (55) and replication (48) occur have been identified.
PML bodies and coiled bodies have been associated with control of
gene expression and undergo modifications in structure and poten-
tially function in cancer cells (52, 56). Because these components of
nuclear architecture have been defined by in situ immunoreactive
proteins and/or ultrastructural imaging as well as by biochemical
criteria, a viable basis has been established for linkage with gene-
regulatory mechanisms.
Mechanisms Mediating Nuclear Structure-Function
Interrelationships
The accumulating evidence for association of genes and regulatory
proteins with components of nuclear architecture, together with long-
standing examples of gene rearrangements and remodeling of chro-
matin organization, reflects functional interrelationships between nu-
clear structure and gene expression at multiple levels. Particularly
significant from a functional perspective, there are changes in the
association and subnuclear distribution of nucleic acids and regulatory
factors that parallel and may be causally related to requirements for
replication and transcription. However, validating linkages between
the architectural organization of regulatory machinery with intranu-
clear distribution of genes and regulatory factors necessitates an
understanding of the mechanisms that control modifications in the
representation, conformation, and subnuclear trafficking in relation to
biological activities.
Genomic Reconfiguration. The most well-documented and mech-
anistically understood perturbations in nuclear organization are mod-
ifications in genomic organization, gene amplification, and rearrange-
ments of gene loci that are prevalent in cancer. Much remains to be
established before the sequence of events that controls gene amplifi-
cation and recombination is fully defined. However, significant pro-
gress has been made in identifying and characterizing the enzymology
of replication and recombination (reviewed in Refs. 57 and 58).
Components of mechanisms that are involved in cleavage, ligation,
and editing are understood for events that are associated with
genomic, viral, and other episomal sequences.
Chromatin Remodeling. During the past several years, there have
been major advances in the ability to experimentally address the
molecular mechanisms that mediate chromatin remodeling (Fig. 1).
This is, to a significant extent, attributable to an increased understand-
ing of the enzymatic control of nucleosome structure and organiza-
tion. ATP-dependent chromatin remodeling enzymes have been iden-
tified, and there is increased insight into the activities of the enzymes
that covalently modify histone proteins.
A family of SWI/SNF-related proteins and protein complexes has
been described in yeast and mammalian cells (1, 59–62) that pro-
motes transcription by altering chromatin structure (61). These ATP-
dependent alterations render DNA sequences containing regulatory
elements accessible for binding cognate transcription factors and
mediate protein-protein interactions that influence the structural and
functional properties of chromatin. Although the mechanisms by
which these complexes function remain to be formally defined, there
is general agreement that the increase in DNA sequence accessibility
does not require the removal of histones (63–65). Rather, multiple
lines of evidence suggest that remodeling of the nucleosomal structure
involves alterations in histone-DNA and/or histone-histone interac-
tions. All chromatin remodeling complexes that have been reported to
date include a subunit containing ATPase activity (59, 60, 66–73) and
have been shown to be critical for modifying nucleosomal organiza-
tion. Because these subunits share significant homology, it has been
suggested that they belong to a new family of proteins with a function
that has been highly conserved throughout evolution (61).
Posttranslational modifications of histones have been implicated in
the physiological control of chromatin structure for the past three
decades. However, recent findings have functionally linked histone
acetylation and phosphorylation with changes in nucleosomal struc-
ture that alter accessibility to specific regulatory elements (1). For
example, acetylation of the amino-termini of nucleosomal histones
has been directly correlated with transcriptional activation. Moreover,
it has been observed that core histone hyperacetylation enhances the
binding of most transcription factors to nucleosomes (74–76). Nev-
ertheless, there have been reports that chromatin hyperacetylation
blocks steroid hormone transcriptional enhancement and steroid-
dependent nucleosomal alterations (77–79). Within this context, it
was recently shown that hyperacetylation of nuclear proteins alters the
chromatin organization of the bone tissue-specific osteocalcin gene
promoter in a manner that prevents vitamin D-mediated transcrip-
tional up-regulation. By combining nuclease accessibility, indirect
end labeling, and ligation-mediated PCR analysis, it was demon-
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Fig. 1. Modified nuclear structure-function interrelationships in cancer. A schematically illustrates the principal components of nuclear architecture that may undergo modifications
linked to altered gene expression in transformed and tumor cells. Insets on the left depict the three principal levels of nuclear organization that support packaging of DNA (gene promoter
organization, nucleosomes, and chromatin). Inset panels on the right illustrate subnuclear foci that support control of gene expression. Each may exhibit pronounced modifications in
composition and/or organization in tumor cells that are linked to perturbations in gene expression (nuclear pores, DNA replication foci, PML foci, RNA polymerase II foci, AML foci,
the nucleolus, and chromatin remodeling complexes). B is a diagram of the enzymatic modifications in chromatin structure that mediate remodeling to accommodate requirements for
competency to bind regulatory factors and support transcription. SWI/SNF factors control ATP-dependent nucleosomal reorganization. Chromatin remodeling is facilitated by the
dynamic acetylation and deacetylation of H4 and H3 histones that modify histone-DNA and histone-histone interactions. These reversible posttranslational modifications of histones
are catalyzed by HDACs and HATs. C and D are diagrams illustrating modifications in the subnuclear organization of gene-regulatory complexes that result from chromosomal
translocations in tumor cells, resulting in alterations in intranuclear trafficking to subnuclear domains. The fidelity of both factor trafficking and gene expression is compromised. C
shows association of AML factors with transcriptionally active domains. AML/ETO foci are not associated with the transcriptionally active form of RNA polymerase II and are
transcriptionally inactive. This nuclear reorganization occurs in AML with the 8;21 chromosomal translocation. D shows the reorganization of PML foci that are characteristic of
promyelocytic leukemias. There is a dramatic transition from a limited number of large foci in normal hematopoietic cells to an increased number of smaller foci in tumor cells.
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strated that protein-DNA interactions that promote the formation of a
distal DNase I-hypersensitive site do not occur under conditions of
hyperacetylation (79). Similarly, Bresnick et al. (77) have reported
that butyrate treatment, which results in chromatin hyperacetylation
by inhibiting HD activities, abolished glucocorticoid hormone-depen-
dent formation of the nuclease-hypersensitive site and blocked tran-
scriptional induction of the MMTV long terminal repeat sequence. In
contrast, Bartsch et al. (80) found that by decreasing the concentra-
tions of HD inhibitors, only moderate acetylation can be obtained.
Moderate acetylation leads to enhanced transcription from the MMTV
promoter in the absence of hormone and potentiates transactivation by
either glucocorticoids or progestins. Because these inducing inhibitor
concentrations lead to a type of nucleosomal DNase I hypersensitivity
similar to that caused by hormone treatment, it was suggested that
moderate acetylation of core histones activated the stably integrated
MMTV promoter by mechanisms involving chromatin remodeling
similar to that generated by the inducing hormones.
A major breakthrough in experimentally addressing the physiolog-
ical role of histone acetylation came with the recent purification and
subsequent cloning of the catalytic subunits of yeast and mammalian
nuclear HATs. Gcn5 encodes a 55-kDa protein in yeast that acetylates
both histones H3 and H4 (81). It has been reported that Gcn5 is part
of a large (1.8-MDa) protein complex designated SAGA (82), which
includes proteins that are also present in complexes involved in
transcriptional regulation (1). Recruitment of SAGA by transcrip-
tional activators results in localized acetylation of nucleosomal sub-
strates in vivo and in vitro (82). Importantly, the transcriptional
stimulatory activity of the recruited SAGA complex is dependent on
its HAT activity (82).
Other proteins that contain nuclear HAT activity are p300 and its
related homologue, CBP (83). These two proteins function as tran-
scriptional adaptors that interact with several transcription factors
including cAMP-responsive element-binding protein, jun, Fos, Myb,
and Myo D, and with nuclear steroid hormone receptors (84–93). In
addition, human TAFII250 and yeast TAFII250 have HAT activity
(94). TAFII250 is part of the transcription factor IID complex that
recognizes the TATA sequence at the promoter region of most genes
and initiates the formation of transcription preinitiation complexes.
The presence of HAT activity in this complex suggests that histone
acetylation may be a requirement for transcription factor interaction
with nucleosomal DNA.
Alterations in mechanisms that mediate the enzymology of histone
modifications in cancer cells support involvement in the onset and/or
progression of tumorigenesis. Relative examples are accumulating
that implicate perturbations in both the acetylation and deacetylation
of histones, and the known biochemical targets are increasing. Very
importantly, in recent years, a direct correlation between abnormal
histone acetylase activity and the potential for cell transformation has
been found. Recent studies show the recruitment of CBP by Smad2/3
proteins in the transforming growth factor b signaling pathway (95,
96). There is evidence that mutation of the players in this pathway
(e.g., Smad2, Smad4, and p300) leads to the development of cancer
(e.g., colorectal carcinomas; Refs. 96 and 97).
P/CAF, another protein that contains HAT activity, is highly ho-
mologous to both the yeast Gcn5 and the human homologue hGcn5.
P/CAF interacts with p300 and CBP to form functional complexes
(98). These findings are consistent with the formation of complexes
containing multiple HAT activities that can accommodate require-
ments for specificity of histone acetylation under different biological
conditions.
Nuclear HAT activity appears to be critical during steroid hormone-
dependent transcriptional activation. It has been reported that coacti-
vation factors that include ACTR and SRC-1 recruit CBP/p300 and
P/CAF to ligand-bound nuclear hormone receptors. SRC-1 and ACTR
(and the related molecules RAC3, AIB1, and TRAM-1) have HAT
activity. This is an example of multiprotein complexes containing
different HAT activities that contribute to modifications of nucleoso-
mal histones that are functionally linked to competency for chromatin
remodeling that occurs during ligand-dependent transcriptional regu-
lation (99). Interestingly, AIB1 is expressed at high levels in breast
cancer, but not in normal breast tissue. In addition, BRCA1 and
BRCA2 are tumor suppressor genes involved in familial breast can-
cers. Both are thought to have roles in transcription, cell cycle control,
and DNA repair. BRCA1 associates with CBP, whereas BRCA2 has
HAT activity (100, 101). Thus, HAT activity may play a role in the
function of these tumor suppressor proteins.
For histone acetylation to be a physiologically relevant component
of transcriptional control, there is a requirement for a cellular mech-
anism to reverse this posttranslational modification. HDs that enzy-
matically remove acetate moieties from histone proteins have been
studied extensively during the past several years. Multiple forms of
this enzyme have been identified and characterized in several organ-
isms (102–106). The mammalian forms designated HDAC1, HDAC2,
and HDAC3 were found to be homologous to the yeast form desig-
nated Rpd3 (107). HDAC1 and HDAC2, but not HDAC3, are large
multiprotein complexes containing corepressor molecules such as
mSin3, N-CoR, or SMRT as well as the proteins SAP18, SAP30,
RbAp48, and RbAp46 (107). The Sin3A-N-CoR-/SMRT-HDAC1/2
complex and other complexes associated with HD activity can be
recruited specifically to gene promoter-regulatory sequences by unli-
ganded nuclear steroid receptors (108, 109). Thus, SAP30, which
binds mSin3 and N-Cor, is required for N-CoR/mSin3-mediated re-
pression of hydroxytamoxifen-bound estrogen receptor (110, 111) but
not unliganded retinoic acid receptor and thyroid receptor. It has been
shown that decreasing the levels of intracellular N-CoR corepressors
can lead to tamoxifen resistance in breast cancer (112).
HDAC1 and HDAC2 are also found in another protein complex
designated NuRD (113). Thus, human NuRD complexes contain not
only ATP-dependent nucleosome disruption activity but also HD
activity that is usually associated with transcriptional repression. The
deacetylation is stimulated by ATP on nucleosomal templates, sug-
gesting that nucleosome disruption facilitates the access of the
deacetylase to its substrates. One subunit of NuRD was identified as
MTA1, a metastasis-associated protein with a region similar to N-
CoR, indicating that ATP-dependent chromatin remodeling can par-
ticipate in transcriptional repression by assisting repressors in gaining
access to chromatin. It has been determined that the levels of MTA1
mRNA and the corresponding protein correlate with the metastatic
potential of several cancer cells (114–116). Although no direct evi-
dence has been reported indicating that higher levels of MTA1 are
required for metastasis to occur, HD complexes have been shown to
interact with Rb to repress transcription (117–119). The mSin3-
associated deacetylases have also been demonstrated to be involved in
acute promyelocytic leukemia (120–122). These results led to the
speculation that aberrant regulation of NuRD activity may alter the
expression of its target genes, leading to metastatic growth potential.
It has been reported recently that HDAC1 and HDAC2 and the
histone-binding proteins RbAp46 and RbAp48 form a core complex
shared between NuRD and Sin-HD complexes (123). A novel
polypeptide highly related to MTA1, MTA2, and the methyl-CpG
binding-domain-containing protein MBD3 were found to be subunits
of the NuRD complex. MTA2 modulates the enzymatic activity of the
HD core complex. MBD3 mediates the association of MTA2 with the
core HD complex. MBD3 does not directly bind methylated DNA, but
it is closely related to MBD2, a protein that binds to methylated DNA
and has been reported to contain demethylase activity. MBD2 inter-
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acts with the NuRD complex and directs the complex to methylated
DNA. These results indicate that NuRD may silence genes by DNA
methylation (123). Interestingly, MBD2 has also been identified as a
colon cancer antigen (124), suggesting a potential involvement of
NuRD-like complexes in colon cell transformation.
Taken together, these findings indicate that in general, histone
acetylation and deacetylation correlate with activation and suppres-
sion of gene expression, confirming that remodeling of chromatin
structure and nucleosome organization is obligatory for physiological
control of transcription. Alterations in mechanisms that mediate the
enzymology of histone modifications can support changes in regula-
tory events that are involved in the onset and/or progression of
tumorigenesis.
Nuclear Matrix-associated Transcriptional Domains. The sub-
nuclear distribution of transcription factors appears to be important for
the fidelity of transcriptional control. As mechanisms that mediate the
various components of transcription factor trafficking are pursued,
additional regulatory parameters of gene expression are being defined.
Nuclear import was the first aspect of transcription factor trafficking
to be addressed. Consequently, the biochemistry of transcription fac-
tor entry to the nucleus is now understood in relation to the structural
and functional properties of the nuclear pore within the context of
linkages between morphology, biochemistry, and regulatory activities.
More recently, attention has turned to nuclear retention and export of
regulatory factors from the standpoints of contributions to factor
activity as well as the regulated and regulatory aspects of subcellular
factor distribution.
The AML transcription factors (also referred to as CBFa, PEBP2a,
and RUNX proteins) that support hematopoietic (125–134) and bone
tissue-specific (16, 18) gene expression have provided a paradigm for
directly examining mechanisms that target regulatory factors to sub-
nuclear sites that support transcription. Functional biochemical and in
situ immunofluorescence analyses of AML deletion and point muta-
tions have provided an indication of how these transcription factors
are directed to nuclear matrix-associated intranuclear domains. It has
been shown that: (a) sequences required for targeting AML factors to
the nuclear matrix reside in a 31-amino acid segment within the
COOH terminus that is physically distinct from the nuclear localiza-
tion signal; (b) nuclear matrix association of AML factors is inde-
pendent of DNA binding activity; (c) the principal active and inactive
splice variants of the AML transcription factors are differentially
localized within the nucleus; and (d) the nuclear matrix targeting
signal of AML factors functions autonomously. These findings dem-
onstrate that at least two trafficking signals are required for subnuclear
targeting of the AML transcription factors; the first supports nuclear
import, and the second mediates association with the nuclear matrix.
Recent results provide insight into the functional consequences of
directing transcripton factors to the nuclear matrix. Invoking the
rationale that guilt by association is biologically relevant, it has been
shown that 31-amino acid nuclear matrix targeting sequence of the
AML transcription factor targets the regulatory protein to a subnuclear
domain that supports transcription. Colocalization of AML with tran-
scriptionally active RNA polymerase II has been demonstrated, as
have requirements for a functional DNA binding domain and ongoing
transcription (135). Functional implications of subnuclear localization
of AML transcription factors are more directly provided by studies
that establish that targeting to the nuclear matrix-associated sites is
obligatory for maximal transactivation activity (35).
From a general biological perspective, there is growing apprecia-
tion of sequence requirements for intranuclear targeting of steroid
hormone receptors [estrogen receptor (136) and glucocorticoid recep-
tor (137–139)] as well as ubiquitous [YY1 (140)] and selectively
utilized [PIT1 (136) and PML (141)] regulatory proteins. Evidence for
a nucleolar targeting domain in parathyroid hormone-related protein
(142) and YY1 (140) has been reported. Taken together, we are
increasing our understanding of mechanisms that mediate the assem-
bly of regulatory components to initiate and sustain transcription
within the context of nuclear architecture.
Integration of Regulatory Cues. We are gaining insight into the
integration of regulatory signals that control expression by mediating
cross-talk between components of signaling pathways that are oper-
ative within the three-dimensional context of nuclear architecture.
There is growing appreciation that mechanisms modulating chromatin
remodeling require the involvement of higher-order nuclear structure
(143). The human SWI/SNF and mouse BAF complexes have been
shown to be associated with the nuclear matrix (144, 145). Functional
implications are provided by the observation that the BAF complex is
only associated with the nuclear matrix after mitogenic stimulation of
T lymphocytes when genes controlling competency for proliferation
and cell cycle progression are activated (145). In resting cells, the
BAF complex is primarily present in the soluble nuclear fraction.
However, immediately after the induction of proliferation (10 min,
90% of the BAF complex is found tightly associated with the nuclear
matrix fraction (145). The specific parameters of chromatin remodel-
ing that are linked to nuclear matrix binding of BAF as well as the
cause and/or effect relationships between BAF activity and parame-
ters of nuclear organization will unquestionably be informative.
Further insight into linkages between nuclear architecture, cytoar-
chitecture, and the regulation of chromatin structure is provided by
recent reports that actin-related proteins are components of chromatin
remodeling complexes (62, 145–147). It has been suggested that these
actin-related and actin-binding proteins may provide a basis for in-
teractions between chromatin remodeling complexes and cytoskeletal
structures involving actin. This suggestion is further supported by
observations that both human SWI/SNF complexes and the Drosoph-
ila BRM complexes not only contain an actin-related protein (BAF 53
in human cells and BAP 55 in Drosophila) but also contain actin (145,
147). Furthermore, regions of BAF that contact myosin, proliferin,
and other actin-binding proteins are similar to actin (145). The pos-
sibility can therefore be considered that such interactions are impor-
tant for SWI/SNF function.
Linkages of Aberrant Nuclear Organization with Modified
Gene Expression in Cancer. Interrelationships of nuclear structure
with gene expression are illustrated by the modified subnuclear orga-
nization of genes and regulatory factors in cancer (Fig. 1). Trans-
formed and tumor cells exhibit striking alterations in nuclear mor-
phology as well as in the representation and intranuclear distribution
of nucleic acids and regulatory factors. In both leukemias and solid
tumors, there are modifications in components of nuclear architecture
that are involved in control of gene expression. Examples include
mutations of the AML, ALL, and PML loci in leukemias that accom-
pany changes in gene expression and the subnuclear organization of
encoded transcription factors. In colon tumor cells, modifications in
the subnuclear distribution of the APC factor are observed (148).
These factors are associated with nuclear architecture, and the alter-
ations in relationships with nuclear architecture appear to be related to
changes in gene control. Identification of nuclear import signals in
transcription factors and the recent characterization of intranuclear
targeting signals that direct regulatory proteins to subnuclear domains
that support transcription reinforce linkages between nuclear structure
and aberrant transcriptional control. These observations provide an
opportunity to develop high-resolution in situ immunofluorescence
analysis to diagnose and stage tumors and to monitor remission,
relapse, and effectiveness of treatment. There is a potential for devel-
oping therapeutics that are directed to subnuclear sites that support
specific components of gene expression.
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Alterations in nuclear organization are the hallmarks of cancer
cells. The gene locus encoding the AML transcription factor is fre-
quently the target of chromosomal translocations in human leukemia.
Replacement of the chromosome 21-encoded intranuclear trafficking
signal by a targeting signal from chromosome 8 redirects the t(8;21)
translocation-fusion protein to unique subnuclear sites. Thus, intranu-
clear targeting of the AML transcription factor may be abrogated
because of gene rearrangements in leukemic cells. Fidelity of tran-
scriptional control may involve the localization of gene-regulatory
proteins to the correct subnuclear region (149).
PML bodies are another example of nuclear structures that are
associated with the nuclear matrix and modified in leukemia cells
(52). In normal cells, the PML protein resides in discrete PML
bodies. However, in promyelocytic leukemic cells, the PML pro-
tein is genetically rearranged and dispersed throughout the nucleus
(52, 150). A further example of chromosomal translocations in-
volving a locus encoding a nuclear matrix-associated transcription
factor occurs in acute lymphocytic leukemia (ALL/MLL). Re-
cently, a translocation has been described in which the ALL/MLL
protein is fused with a HAT. This chimeric protein may promote
leukemia by modifying histone acetylation of specific genomic
regions. Consequential modifications in the intranuclear distribu-
tion of factors encoded by the rearranged ALL locus occur (151–
153), although the chimeric transcription factors remain nuclear
matrix associated (154). Hence, these results suggest that pertur-
bations in subnuclear location of regulatory proteins may be re-
lated to modifications in gene expression that are linked to leuke-
mias. Additionally, tumor-associated modifications have been
observed in nuclear domains that support the processing of tran-
scripts, the intranuclear organization of Rb and DNA replication
foci, and the nucleocytoplasmic shuttling of p53 that has been
functionally linked to association of Mdm2 with the nucleolus
(155–157).
Perspectives and Future Directions
It is well documented that components of nuclear architecture
contribute both structurally and enzymatically to control of gene
expression. The historic distinction between morphology and func-
tional activity has given way to acceptance that the organization of
nucleic acids and regulatory proteins within the cell nucleus is linked
to biological control and aberrant gene expression that occurs during
the onset and progression of cancer. A road map of regulatory events
that mediate transcriptional control within the three-dimensional con-
text of nuclear architecture has been established. A bidirectional
exchange of gene transcripts and regulatory factors between the
nucleus and cytoplasm as well as between regions and structures
within the nucleus has been defined. Responsiveness to a broad
spectrum of signaling pathways is being pursued experimentally along
with mechanisms that target regulatory factors to subnuclear sites
where the machinery for gene expression is assembled, rendered
operative, and/or suppressed. However, it would be naive to anticipate
a single target for tumor-related alterations in the organization of
genes, transcripts, and regulatory machinery. Rather, the challenge we
now face is to experimentally define the mechanisms that mediate
each component of gene regulation in relation to nuclear structure-
function relationships. There is growing recognition that placement of
regulatory components of gene expression must be temporally and
spatially coordinated to optimally support biological control. The
consequences of breaches in nuclear structure-function interrelation-
ships that have been observed in an extensive series of tumors provide
options for high-resolution diagnosis and targeted therapies.
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